New review explores effect of HPV vaccination on cervical cancer screening

NewsGuard 100/100 Score

A new review looks at cervical cancer screening in the era of HPV vaccination. The review notes that trials have demonstrated the efficacy and safety of vaccines against HPV infection, but the complete effect of HPV vaccination as a cancer prevention strategy may not be fully evident for decades, given the slow progression from HPV infection to the development of cervical cancer.

Also, studies have found a positive correlation between HPV vaccination and cervical screening, in spite of a perception that vaccination would lead to patients' reassurance and decreased cervical cancer screening. Research also found no significant changes in the percentage of women reporting sexual activity or number of sexual partners between the pre- and post-vaccination era.

Vaccine cost and low provider recommendation are significant barriers for widespread HPV vaccination in the United States.

"Based on overwhelming data, it seems that the time has come for HPV testing and vaccination to take the front seat in the prevention of cervical cancer," said Dr. Julieta Barroeta, lead author of the Diagnostic Cytopathology review.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
New cancer projections show increased prostate cases by 25% in 2050, despite prevention efforts